Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902595 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1EPHX1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL9903633 | 0.78 | DRD4 (0.39) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9901315 | 0.77 | ALDH1A1 (0.50) | ALDH1A1EPHX1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL9903230 | 0.76 | ALDH1A1 (0.54) | ALDH1A1EPHX2 | |
| SCHEMBL9902315 | 0.75 | EPHX1 (0.49) | ALDH1A1EPHX1EPHX2RAB9ATSHR | |
| SCHEMBL9902657 | 0.70 | ALDH1A1 (0.52) | ALDH1A1EPHX2 | |
| SCHEMBL9901463 | 0.70 | ALDH1A1 (0.53) | ALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL9902047 | 0.70 | MAPK1 (0.38) | ALDH1A1EPHX1SMN1; SMN2TSHR | |
| SCHEMBL9901557 | 0.69 | CTSL (0.46) | ALDH1A1EPHX1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL9903173 | 0.69 | EPHX1 (0.47) | ALDH1A1EPHX1EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | ALDH1A1 1804/4885EPHX1 1397/4885EPHX2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.